| Title |
Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study
|
|---|---|
| Published in |
Diabetologia, January 2012
|
| DOI | 10.1007/s00125-011-2447-3 |
| Pubmed ID | |
| Authors |
B. Eliasson, D. Möller-Goede, K. Eeg-Olofsson, C. Wilson, J. Cederholm, P. Fleck, M. Diamant, M.-R. Taskinen, U. Smith |
| Abstract |
Pharmacological augmentation of glucagon-like peptide 1 receptor signalling by dipeptidyl peptidase 4 (DPP-4) inhibition reduced intestinal lipoprotein secretion in experimental studies, suggesting that DPP-4 inhibitors may ameliorate dyslipidaemia and thus reduce cardiovascular risk in patients with type 2 diabetes. We assessed the effects of alogliptin (Alo) and Alo co-administered with pioglitazone (Pio) vs placebo (Pbo) on triacylglycerol (TG)-rich lipoproteins in type 2 diabetes before and following a high-fat meal. |
Mendeley readers
The data shown below were compiled from readership statistics for 113 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 2 | 2% |
| United Kingdom | 1 | <1% |
| Brazil | 1 | <1% |
| Mexico | 1 | <1% |
| Denmark | 1 | <1% |
| Spain | 1 | <1% |
| Japan | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 104 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 21 | 19% |
| Student > Master | 20 | 18% |
| Other | 11 | 10% |
| Student > Ph. D. Student | 10 | 9% |
| Professor | 8 | 7% |
| Other | 27 | 24% |
| Unknown | 16 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 55 | 49% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 9% |
| Agricultural and Biological Sciences | 10 | 9% |
| Nursing and Health Professions | 9 | 8% |
| Biochemistry, Genetics and Molecular Biology | 3 | 3% |
| Other | 8 | 7% |
| Unknown | 18 | 16% |